Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway.

By K. Ohaegbulam, Amer Assal, E. Lázár-Molnár, Yu Yao, X. Zang. Trends in Molecular Medicine, 2015

782 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome (2017, background): “This conversion increases Treg expression and immune suppressive function of CD4+ T-cell through inhibition of mammalian target of rapamycin (mTOR)-Akt signaling cascade (Ohaegbulam et al., 2015).”
Overcoming T cell exhaustion in infection and cancer (2015, background): “While PD-L1 expression in the tumor has been associated with poor prognosis in several settings [24], recent clinical data showed that PD-L1 expression on immune infiltrates in the tumor positively correlated with responsiveness to anti-PD-L1 immunotherapy [28, 29].”
RosettaAntibodyDesign (RAbD): A general framework for computational antibody design (2017, background): “many targets, these methods may not produce antibodies with desirable properties, because the antigen is difficult to target[20-22] or because the antibody is required to bind to a specific epitope for various functional reasons such as the neutralization of a target pathogen[23], initialization of ”
Mechanisms controlling PD-L1 expression in cancer (2019, background): “, 2004), high PD-L1 expression is detected and associated with poor prognosis (Ohaegbulam et al., 2015).”
PD-L1 expression in human cancers and its association with clinical outcomes (2016, neutral): “The overall response rates achieved was 16%–100%.(3,42) Consequently, an effective”